Home
>
National Drug Code (NDC)
>
RAPAFLO
RAPAFLO - 52544-152-19 - (silodosin)
Drug Information of RAPAFLO
| Product NDC: | 52544-152 |
| Proprietary Name: | RAPAFLO |
| Non Proprietary Name: | silodosin |
| Active Ingredient(s): | 8 mg/1 & nbsp; silodosin |
| Administration Route(s): | ORAL |
| Dosage Form(s): | CAPSULE |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of RAPAFLO
| Product NDC: | 52544-152 |
| Labeler Name: | Watson Pharma, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA022206 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20090323 |
Package Information of RAPAFLO
| Package NDC: | 52544-152-19 |
| Package Description: | 90 CAPSULE in 1 BOTTLE, UNIT-DOSE (52544-152-19) |
NDC Information of RAPAFLO
| NDC Code | 52544-152-19 |
| Proprietary Name | RAPAFLO |
| Package Description | 90 CAPSULE in 1 BOTTLE, UNIT-DOSE (52544-152-19) |
| Product NDC | 52544-152 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | silodosin |
| Dosage Form Name | CAPSULE |
| Route Name | ORAL |
| Start Marketing Date | 20090323 |
| Marketing Category Name | NDA |
| Labeler Name | Watson Pharma, Inc. |
| Substance Name | SILODOSIN |
| Strength Number | 8 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Adrenergic alpha-Antagonists [MoA],alpha-Adrenergic Blocker [EPC] |
